Gateway Health℠ It's Wholecare.

Updated: 05/2020
PARP Approved: 05/2020

Prior Authorization Criteria
Firdapse (amifampridine)

All requests for Firdapse (amifampridine) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Firdapse (amifampridine) Prior Authorization Criteria:

Coverage may be provided with a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) and the following criteria is met:

- Member is 18 years of age or older
- The prescribing physician is a neurologist
- Must provide documentation of muscle weakness with typical distribution, areflexia, autonomic dysfunction, and **ONE** of the following:
    - Presence of VGCC autoantibodies
    - Electromyograph (EMG) or Nerve Conduction Study (NCS) with adequate repetitive stimulation undertaken in relevant muscles
- Provider attestation that other differential diagnoses such as Myasthenia Gravis have been ruled out
- Provider attestation that the member does not have a history of seizures
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 3 months
- **Reauthorization criteria**
    - Must provide chart documentation demonstrating improvement or stabilization of muscle weakness from baseline and tolerance
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

Gateway Health℠ It's Wholecare.

Updated: 05/2020
PARP Approved: 05/2020

FIRDAPSE (AMIFAMPRIDINE) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway Health℠ Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative.
PHONE: (800) 392-1147 Monday through Friday 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:
Gateway ID:	Member weight: _____pounds or _____kg

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? ☐ Yes ☐ No		

Billing Information

This medication will be billed: ☐ at a pharmacy **OR**
☐ medically (if medically please provide a JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis: _____
Is documentation of muscle weakness, areflexia, and autonomic dysfunction provided? ☐ Yes ☐ No
Is documentation of VGCC autoantibodies, an electromyograph, or nerve conduction study provided? ☐ Yes ☐ No
Has Myasthenia Gravis or other differential diagnoses been ruled out? ☐ Yes ☐ No
Does the member have a history of seizures? ☐ Yes ☐ No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Has the member experienced a significant improvement with treatment? ☐ Yes ☐ No
Please describe:

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date